Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Risperdal Consta Priced Comparable To Zyprexa; Clears FDA Oct. 29

Nov 03 2003

• By The Pink Sheet

Related Content

J&amp;J Patches Together Strong Sales Growth With Ortho EVRA, Duragesic

Oct 20 2003

J&amp;J Finalizing Risperdal Consta Resubmission; Approval Possible By Year-End

Apr 21 2003

FDA Sides With Lilly; Seeks Class Warning On Antipsychotic Diabetes Risk

Sep 22 2003

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window